



PERSONAL GENOME DIAGNOSTICS' SCIENTISTS RATED AS AMONG WORLD'S MOST INFLUENTIAL

—Four Scientists Associated with PGDx are Included in Thomson Reuters' "Highly Cited Researchers" Listing, Spotlighting the Most Influential Researchers of the Past Decade—

BALTIMORE, MD, July 19 2014 – Personal Genome Diagnostics Inc. (PGDx), a provider of advanced cancer genome analysis and testing services, reported that four scientists associated with the company are included in the Thomson Reuters' report, [The World's Most Influential Scientific Minds: 2014](#), which presents a compilation of the most highly cited researchers of the last decade. The listing includes PGDx co-founder and chief scientific officer Victor Velculescu, MD, PhD, and director of bioinformatics and IT Samuel Angiuoli, PhD. In addition, PGDx founding scientific advisors Bert Vogelstein MD, and Ken Kinzler, PhD, are also included among the most [Highly Cited Researchers](#).

Antony Newton, chief commercial officer of PGDx noted, "PGDx was founded by leading cancer researchers with the mission of making our expertise at the forefront of cancer genomics widely available to other researchers, drug developers and ultimately physicians and patients. We are gratified that Thomson Reuters' worldwide assessment confirmed what we already knew – that the scientific output of our colleagues has been judged by peers to be of particular significance and utility over a decade that witnessed tremendous advances in cancer genomics."

The report identifies more than 3,000 authors in 21 fields of science and the social sciences. These researchers earned their inclusion among the highly cited researchers by authoring the greatest numbers of scientific papers between 2002 and 2012 that were officially designated as Highly Cited Papers—ranking among the top 1% most cited for their subject field and year of publication over the decade. Thomson Reuters collaborated with Shanghai Jiao Tong University to create the Highly Cited Researchers listing for 2014.

About Personal Genome Diagnostics

Personal Genome Diagnostics (PGDx) provides advanced cancer genome analyses to oncology researchers, drug developers, clinicians and patients. The company uses advanced genomic methods and its deep expertise in cancer biology to identify and characterize the unique genomic alterations in tumors. PGDx's proprietary methods for genome sequencing and analysis are complemented by its extensive experience in cancer genomics and clinical oncology. The founders of PGDx, Luis Diaz, MD, and Victor Velculescu, MD, PhD, are internationally recognized leaders in cancer genomics at Johns Hopkins University who have extensive experience in the practical application of advanced genomic technologies to drug development and clinical practice. PGDx's CLIA-certified facility provides personalized cancer genome analyses to patients and their physicians. For more information, visit www.personalgenome.com.

###